1. Home
  2. AGIO vs CENX Comparison

AGIO vs CENX Comparison

Compare AGIO & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • CENX
  • Stock Information
  • Founded
  • AGIO 2007
  • CENX 1995
  • Country
  • AGIO United States
  • CENX United States
  • Employees
  • AGIO N/A
  • CENX N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • CENX Aluminum
  • Sector
  • AGIO Health Care
  • CENX Industrials
  • Exchange
  • AGIO Nasdaq
  • CENX Nasdaq
  • Market Cap
  • AGIO 1.4B
  • CENX 1.5B
  • IPO Year
  • AGIO 2013
  • CENX 1996
  • Fundamental
  • Price
  • AGIO $32.09
  • CENX $15.49
  • Analyst Decision
  • AGIO Buy
  • CENX Strong Buy
  • Analyst Count
  • AGIO 8
  • CENX 3
  • Target Price
  • AGIO $56.00
  • CENX $23.00
  • AVG Volume (30 Days)
  • AGIO 550.4K
  • CENX 1.5M
  • Earning Date
  • AGIO 05-01-2025
  • CENX 05-07-2025
  • Dividend Yield
  • AGIO N/A
  • CENX N/A
  • EPS Growth
  • AGIO N/A
  • CENX N/A
  • EPS
  • AGIO 11.45
  • CENX 1.22
  • Revenue
  • AGIO $37,035,000.00
  • CENX $2,364,700,000.00
  • Revenue This Year
  • AGIO $27.43
  • CENX $6.79
  • Revenue Next Year
  • AGIO $189.81
  • CENX $3.58
  • P/E Ratio
  • AGIO $2.80
  • CENX $12.69
  • Revenue Growth
  • AGIO 25.96
  • CENX 11.41
  • 52 Week Low
  • AGIO $23.42
  • CENX $11.40
  • 52 Week High
  • AGIO $62.58
  • CENX $25.39
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 65.51
  • CENX 42.35
  • Support Level
  • AGIO $29.05
  • CENX $15.16
  • Resistance Level
  • AGIO $30.45
  • CENX $16.36
  • Average True Range (ATR)
  • AGIO 1.13
  • CENX 0.62
  • MACD
  • AGIO 0.33
  • CENX -0.04
  • Stochastic Oscillator
  • AGIO 91.98
  • CENX 13.58

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About CENX Century Aluminum Company

Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.

Share on Social Networks: